On Thursday, 5 May at 5.30 PM, LCA – in collaboration with Goodwin – will host the webinar “The NASDAQ IPO Path for Italian Life Science Companies: Genenta Science’s Case Study”, which will involve Assobiotec with Aparna Beeram (Roth Capital Partners), Federica Draghi (Genextra), Andrea Messuti (LCA), Pierluigi Paracchi (Genenta Science), Ettore Santucci (Goodwin).
Starting from Genenta’s successful IPO on Nasdaq, the aim of the webinar is to provide an overview of the challenges and opportunities for companies that want to prepare for the listed market, with a focus on the Life Sciences world.
What are the key attributes of a company to be suitable for a NASDAQ IPO, what critical features public market investors look for when evaluating the issuer’s potential as a successful listed company, and how the Italian ecosystem supports and sustains companies in their early stages to get prepared for the listed market: these are some of the topics that the speakers will point out during the event.
The webinar will be held in English and it will last about 90 minutes, ending with a Q&A session.
Participation is free of charge. Fill in the registration to receive the access link: https://www.lcalex.it/en/the-nasdaq-ipo-path-for-italian-life-science-companies/